Ibrutinib and novel BTK inhibitors in clinical development

Small molecule inhibitors targeting dysregulated pathways (RAS/RAF/MEK, PI3K/AKT/mTOR, JAK/STAT) have significantly improved clinical outcomes in cancer patients. Recently Bruton’s tyrosine kinase (BTK), a crucial terminal kinase enzyme in the B-cell antigen receptor (BCR) signaling pathway, has eme...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Akinleye, Akintunde, Chen, Yamei, Mukhi, Nikhil, Song, Yongping, Liu, Delong
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2013
Gaiak:
Review
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3751776/
https://ncbi.nlm.nih.gov/pubmed/23958373
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-8722-6-59
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak